@entity0 is the most common @entity5 in @entity1 in the United States. The addition of @entity8253 to adjuvant therapy regimens has resulted in improvement in overall survival of @entity1 . The 2 most commonly used @entity8253 are @entity632 and @entity1259 . Comparison studies in the metastatic setting have shown that, at similar doses, these 2 @entity8253 provide similar response rates. However, their @entity137 profiles differ somewhat. The major side effects of @entity8253 are @entity1370 and myelosuppression. The equimolar dose ratios of @entity632 to @entity1259 for myelosuppression and @entity1370 are 1:1.2 and 1:1.7-2.0, respectively. There have been many studies comparing different schedules and doses of @entity8253 in the adjuvant setting. However, direct comparisons between @entity632 and @entity1259 in @entity0 have not been performed to date. In this article, we are attempting to provide an overview of current use of @entity632 and @entity1259 in @entity0

@entity1259 versus XXXX : which is the anthracycline of choice for the treatment of @entity0 ?

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer', 'early-stage breast cancer'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxicity']
@entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']
